AN2 Therapeutics, Inc. (ANTX)
Largest Insider Buys in Sector
ANTX Stock Price History Chart
ANTX Stock Performance
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Insider Activity of AN2 Therapeutics, Inc.
Over the last 12 months, insiders at AN2 Therapeutics, Inc. have bought $2.04M and sold $3.83M worth of AN2 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at AN2 Therapeutics, Inc. have bought $18.22M and sold $5.19M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $12.48M. Readnour Robin Shane (director) — $405,521. Zakrzewski Joseph S (director) — $111,384.
The last purchase of 10,000 shares for transaction amount of $14,930 was made by Readnour Robin Shane (director) on 2024‑12‑10.
List of Insider Buy and Sell Transactions, AN2 Therapeutics, Inc.
| 2025-01-03 | Sale | See Remarks | 9,663 0.0304% | $1.34 | $12,958 | -10.56% | ||
| 2025-01-03 | Sale | Chief Strategy Officer | 2,029 0.0064% | $1.34 | $2,721 | -10.56% | ||
| 2025-01-03 | Sale | Chief Financial Officer | 2,957 0.0093% | $1.34 | $3,965 | -10.56% | ||
| 2025-01-03 | Sale | Chief Development Officer | 2,957 0.0093% | $1.34 | $3,965 | -10.56% | ||
| 2024-12-10 | director | 10,000 0.0329% | $1.49 | $14,930 | -8.61% | |||
| 2024-12-09 | director | 30,772 0.104% | $1.43 | $43,984 | -2.82% | |||
| 2024-12-06 | director | 19,228 0.0635% | $1.45 | $27,795 | -4.17% | |||
| 2024-11-27 | director | 50,000 0.142% | $1.42 | $70,840 | +2.55% | |||
| 2024-11-27 | director | 2,000 0.0056% | $1.40 | $2,800 | +2.55% | |||
| 2024-11-26 | director | 25,000 0.0698% | $1.39 | $34,845 | +0.72% | |||
| 2024-11-20 | director | 50,000 0.116% | $1.16 | $57,870 | +6.92% | |||
| 2024-11-19 | director | 150,000 0.3112% | $1.04 | $155,258 | +31.13% | |||
| 2024-11-19 | director | 5,000 0.0101% | $1.01 | $5,050 | +31.13% | |||
| 2024-11-18 | Chief Executive Officer | 50,000 0.1001% | $1.00 | $49,970 | +39.00% | |||
| 2024-11-18 | director | 20,000 0.0401% | $1.00 | $19,996 | +39.00% | |||
| 2024-08-14 | 10 percent owner | 1.5M 3.1264% | $1.04 | $1.56M | +3.33% | |||
| 2024-08-09 | Sale | 10 percent owner | 3.53M 7.6298% | $1.08 | $3.81M | +4.85% | ||
| 2024-01-18 | Sale | director | 100,000 3.8307% | $19.11 | $1.91M | -89.45% | ||
| 2024-01-16 | Sale | director | 100,000 3.9381% | $19.65 | $1.97M | -89.69% | ||
| 2024-01-16 | Sale | 10 percent owner | 100,000 3.9381% | $19.65 | $1.97M | -89.69% |
Insider Historical Profitability
| Leonard Braden Michael | 10 percent owner | 5749432 19.2425% | $1.27 | 1 | 0 | |
| Easom Eric | Chief Executive Officer | 1065766 3.567% | $1.27 | 2 | 17 | +61.1% |
| Readnour Robin Shane | director | 652573 2.1841% | $1.27 | 8 | 2 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 300853 1.0069% | $1.27 | 9 | 1 | +3.7% |
| Zakrzewski Joseph S | director | 125199 0.419% | $1.27 | 3 | 1 | |
| Eizen Joshua M | See Remarks | 116672 0.3905% | $1.27 | 0 | 1 | |
| Prior Stephen David | Chief Strategy Officer | 33313 0.1115% | $1.27 | 0 | 1 | |
| Day Lucy | Chief Financial Officer | 32670 0.1093% | $1.27 | 0 | 1 | |
| Chanda Sanjay | Chief Development Officer | 29824 0.0998% | $1.27 | 0 | 1 | |
| Shah Rajeev M. | 3773417 12.629% | $1.27 | 5 | 0 | +11.29% | |
| Adjuvant Global Health Technology Fund DE, L.P. | 2210735 7.399% | $1.27 | 1 | 0 | <0.0001% | |
| Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 377542 1.2636% | $1.27 | 1 | 10 | <0.0001% |
| Aziz Kabeer | director | 377542 1.2636% | $1.27 | 1 | 10 | <0.0001% |
| Krause Kevin Michael | Chief Strategy Officer | 1914 0.0064% | $1.27 | 0 | 2 |